Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2023-05-15 Purchase |
2023-05-15 8:01 pm |
AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer |
10,000 | $5.377 | $53,770 | 1,214,789 (Indirect Direct) |
View |
| 2022-11-10 Sale |
2022-11-14 8:48 pm |
AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer |
4,436 | $15.32 | $67,974 | 4,907 (Direct) |
View |
| 2022-11-08 Sale |
2022-11-09 8:33 pm |
AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer |
17,166 | $15.6 | $267,794 | 4,907 (Direct) |
View |
| 2022-11-03 Sale |
2022-11-07 8:19 pm |
AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer |
35,196 | $15.86 | $558,274 | 4,907 (Direct) |
View |
| 2022-10-31 Sale |
2022-11-02 8:52 pm |
AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer |
4,232 | $15.27 | $64,625 | 4,907 (Direct) |
View |
| 2022-10-27 Sale |
2022-10-28 8:27 pm |
AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer |
2,607 | $15.18 | $39,582 | 4,907 (Direct) |
View |
| 2022-10-24 Sale |
2022-10-26 9:19 pm |
AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer |
9,350 | $15.76 | $147,358 | 4,907 (Direct) |
View |
| 2022-10-20 Sale |
2022-10-24 9:44 pm |
AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer |
21,244 | $16.47 | $349,912 | 4,907 (Direct) |
View |
| 2022-08-03 Purchase |
2022-08-05 4:06 pm |
AN2 Therapeutics Inc. | ANTX | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. 10% Owner |
1,909 | $7.5067 | $14,330 | 3,773,517 (Indirect) |
View |
| 2022-07-26 Purchase |
2022-07-28 5:16 pm |
AN2 Therapeutics Inc. | ANTX | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. 10% Owner |
23,219 | $7.7813 | $180,675 | 3,771,608 (Indirect) |
View |
| 2022-03-29 Purchase(A) |
2022-06-24 4:51 pm |
AN2 Therapeutics Inc. | ANTX | Adjuvant Global Health Technology Fund L.P. Adjuvant Global Health Technology Fund DE L.P. Adjuvant Capital GP L.P. Adjuvant Capital Management LLC 10% Owner |
166,666 | $15 | $2,499,990 | 2,597,380 (Indirect Direct) |
View |
| 2022-06-21 Purchase |
2022-06-23 4:31 pm |
AN2 Therapeutics Inc. | ANTX | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. 10% Owner |
302 | $7.99 | $2,413 | 3,748,389 (Indirect) |
View |
| 2022-06-13 Purchase |
2022-06-15 4:25 pm |
AN2 Therapeutics Inc. | ANTX | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. 10% Owner |
81,424 | $7.951 | $647,402 | 3,748,087 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2023-02-23 Option Award |
2023-02-24 5:36 pm |
N/A 2033-02-22 |
AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer |
267,650 | $0 | 267,650 (Direct) |
View |
| 2023-02-15 Option Award |
2023-02-17 7:29 pm |
N/A 2033-02-14 |
AN2 Therapeutics Inc. | ANTX | Day Lucy Chief Financial Officer |
82,300 | $0 | 82,300 (Direct) |
View |
| 2023-02-15 Option Award |
2023-02-17 7:28 pm |
N/A 2033-02-14 |
AN2 Therapeutics Inc. | ANTX | Chanda Sanjay Chief Development Officer |
57,950 | $0 | 57,950 (Direct) |
View |
| 2023-02-15 Option Award |
2023-02-17 7:25 pm |
N/A 2033-02-14 |
AN2 Therapeutics Inc. | ANTX | Eckburg Paul Chief Medical Officer |
70,950 | $0 | 70,950 (Direct) |
View |
| 2023-02-15 Option Award |
2023-02-17 7:24 pm |
N/A 2033-02-14 |
AN2 Therapeutics Inc. | ANTX | Eizen Joshua M Chief Legal Officer |
50,150 | $0 | 50,150 (Direct) |
View |
| 2023-02-15 Option Award |
2023-02-17 7:23 pm |
N/A 2033-02-14 |
AN2 Therapeutics Inc. | ANTX | Nazak Michael Adrian Chief Accounting Officer |
16,600 | $0 | 16,600 (Direct) |
View |
| 2023-02-15 Option Award |
2023-02-17 7:19 pm |
N/A 2033-02-14 |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
62,200 | $0 | 62,200 (Direct) |
View |
| 2022-10-14 Option Award |
2022-10-28 6:03 pm |
N/A 2032-10-13 |
AN2 Therapeutics Inc. | ANTX | Eizen Joshua M Chief Legal Officer |
92,000 | $0 | 92,000 (Direct) |
View |
| 2022-06-06 Other |
2022-06-24 5:10 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director 10% Owner |
26,511 | $15 | 466,178 (Indirect) |
View |
| 2022-06-06 Other |
2022-06-24 5:06 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Adjuvant Global Health Technology Fund L.P. Adjuvant Global Health Technology Fund DE L.P. Adjuvant Capital GP L.P. Adjuvant Capital Management LLC 10% Owner |
26,511 | $15 | 2,650,402 (Direct) |
View |
| 2022-03-29 Conversion(A) |
2022-06-24 4:51 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Adjuvant Global Health Technology Fund L.P. Adjuvant Global Health Technology Fund DE L.P. Adjuvant Capital GP L.P. Adjuvant Capital Management LLC 10% Owner |
2,430,714 | $0 | 2,597,380 (Direct) |
View |
Ownership(A) |
2022-06-24 4:48 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Adjuvant Global Health Technology Fund L.P. Adjuvant Global Health Technology Fund DE L.P. Adjuvant Capital GP L.P. Adjuvant Capital Management LLC 10% Owner |
0 | $0 | 2,430,714 (Direct) |
View |
| 2022-05-12 Option Award |
2022-05-16 9:32 pm |
N/A 2032-05-11 |
AN2 Therapeutics Inc. | ANTX | Chanda Sanjay Chief Development Officer |
66,000 | $0 | 66,000 (Direct) |
View |
| 2022-05-12 Option Award |
2022-05-16 9:25 pm |
N/A 2032-05-11 |
AN2 Therapeutics Inc. | ANTX | Readnour Robin Shane Director |
20,724 | $0 | 20,724 (Direct) |
View |
| 2022-05-12 Option Award |
2022-05-16 9:23 pm |
N/A 2032-05-11 |
AN2 Therapeutics Inc. | ANTX | Eckburg Paul Chief Medical Officer |
66,000 | $0 | 66,000 (Direct) |
View |
| 2022-05-12 Option Award |
2022-05-16 9:22 pm |
N/A 2032-05-11 |
AN2 Therapeutics Inc. | ANTX | Martin Patricia A. Director |
10,362 | $0 | 10,362 (Direct) |
View |
| 2022-05-12 Option Award |
2022-05-16 9:22 pm |
N/A 2032-05-11 |
AN2 Therapeutics Inc. | ANTX | Wong Stephanie Director |
10,362 | $0 | 10,362 (Direct) |
View |
| 2022-05-12 Option Award |
2022-05-16 9:21 pm |
N/A 2032-05-11 |
AN2 Therapeutics Inc. | ANTX | Nazak Michael Adrian Chief Accounting Officer |
14,300 | $0 | 14,300 (Direct) |
View |
| 2022-05-12 Option Award |
2022-05-16 9:20 pm |
N/A 2032-05-11 |
AN2 Therapeutics Inc. | ANTX | FitzPatrick Margaret M Director |
10,362 | $0 | 10,362 (Direct) |
View |
| 2022-05-12 Option Award |
2022-05-16 9:19 pm |
N/A 2032-05-11 |
AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director |
20,724 | $0 | 20,724 (Direct) |
View |
| 2022-05-12 Option Award |
2022-05-16 9:18 pm |
N/A 2032-05-11 |
AN2 Therapeutics Inc. | ANTX | Spigelman Melvin K Director |
10,362 | $0 | 10,362 (Direct) |
View |
| 2022-05-12 Option Award |
2022-05-16 9:16 pm |
N/A 2032-05-11 |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
66,000 | $0 | 66,000 (Direct) |
View |
| 2022-05-12 Option Award |
2022-05-16 9:15 pm |
N/A 2032-05-11 |
AN2 Therapeutics Inc. | ANTX | Day Lucy Chief Financial Officer |
66,000 | $0 | 66,000 (Direct) |
View |
| 2022-05-12 Option Award |
2022-05-16 9:11 pm |
N/A 2032-05-11 |
AN2 Therapeutics Inc. | ANTX | Zakrzewski Joseph S Director |
10,362 | $0 | 10,362 (Direct) |
View |
| 2022-05-12 Option Award |
2022-05-16 9:11 pm |
N/A 2032-05-11 |
AN2 Therapeutics Inc. | ANTX | Marks Gilbert Lynn Director |
10,362 | $0 | 10,362 (Direct) |
View |
| 2022-05-12 Option Award |
2022-05-16 9:10 pm |
N/A 2032-05-11 |
AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer |
225,000 | $0 | 225,000 (Direct) |
View |
| 2022-05-05 Option Award |
2022-05-09 9:39 pm |
N/A 2032-05-04 |
AN2 Therapeutics Inc. | ANTX | FitzPatrick Margaret M Director |
11,463 | $0 | 11,463 (Direct) |
View |